![ShareCast](https://static.lse.co.uk/images/news-logos/sharecast-news-logo.png)
MaxCyte begins dosing second cohort in MCY-M11 clinical trial
(Sharecast News) - Clinical-stage, cell-based therapies and life sciences company MaxCyte has initiated dosing for the second cohort of patients in its US phase 1 clinical trial with MCY-M11 - the lead, wholly-owned, non-viral mRNA-based cell therapy candidate from its CARMA platform - it announced on Wednesday.
Read more